Supplementary Material for: Use of preoperative immunotherapy in locally advanced unresectable cutaneous squamous cell carcinoma – a case report

Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease, however, for large head and neck cSCCs it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting.
Case Presentation: Here, we report the case of a 84-year-old man with two locally advanced unresectable sSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial response of the nasolabial lesion after 4 cycles. Patient will be submitted to nasolabial lesion resection.
Conclusion:This illustrates the efficacy of the use of cemiplimab as preoperative therapy in advanced unresectable cSCC, facilitating a definitive surgical treatment.